Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

Iterum Therapeutics (ITRM) reported its Q4 and full-year 2024 financial results, highlighting the FDA approval of ORLYNVAH™ for uncomplicated urinary tract infections (uUTIs). The company ended 2024 with $24.1 million in cash and cash equivalents, expecting to fund operations into second half of 2025.

Key financial metrics for 2024 include: R&D expenses decreased to $10.5 million from $40.0 million in 2023; G&A expenses increased to $8.0 million from $7.5 million in 2023. Net loss for 2024 was $24.8 million, improved from $38.4 million in 2023. The company repaid its Exchangeable Notes in January 2025 and expanded its patent estate with a new Australian patent allowance extending to 2039.

Positive

• FDA approval of ORLYNVAH™ for uUTIs - first branded uUTI product in US market in over 25 years
• Reduced net loss to $24.8M in 2024 from $38.4M in 2023
• Significant decrease in R&D expenses to $10.5M from $40.0M year-over-year
• Patent estate expansion with Australian patent protection until 2039

Negative

• Increased G&A expenses to $8.0M from $7.5M year-over-year
• Ongoing cash burn requiring additional funding through ATM offering
• Fair value adjustment of Royalty-Linked Notes increased liabilities by $3.3M in 2024

Insights

Financial Analyst

Iterum Therapeutics' Q4 and FY2024 results reveal a strategic transformation following the FDA approval of ORLYNVAH™, marking a pivotal shift from R&D to commercialization. The financial metrics demonstrate improved operational efficiency with R&D expenses significantly decreasing to $10.5M from $40.0M in 2023, reflecting the completion of major clinical trials.

The company's cash position of $24.1M, supplemented by $4.8M from recent ATM offerings, provides runway into H2 2025. This timeline is important as it covers the critical pre-commercialization phase of ORLYNVAH™. The strategic debt management through the repayment of Exchangeable Notes in January 2025 strengthens the balance sheet and reduces future interest obligations.

The expansion of patent protection in Australia until 2039 significantly enhances ORLYNVAH's commercial potential. As the first branded uUTI product in 25 years and the only oral penem approved in the U.S., ORLYNVAH™ addresses a substantial market opportunity in treating multi-drug resistant infections.

While G&A expenses increased to $8.0M from $7.5M, this reflects necessary investments in pre-commercialization activities and legal infrastructure. The reduction in net loss to $24.8M from $38.4M demonstrates improved financial discipline during this transitional phase.

--ORLYNVAH^TM Approved by FDA in Q4 2024—

--Extended Cash Runway--

--Company to host conference call today at 8:30amET--

DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024.

“While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAH^TM is made available to patients as soon as possible to address the substantial unmet need for effective treatment options for uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Iterum’s Chief Executive Officer. “ORLYNVAH^TM will potentially be the first branded uUTI product to enter the U.S. market in over 25 years and the first and only oral penem approved for use in the U.S.”

Highlights and Recent Events

• Approval by U.S. Food and Drug Administration (FDA) of ORLYNVAH^TM for uUTIs: In the fourth quarter of 2024, Iterum received approval from the FDA of its new drug application (NDA) for ORLYNVAH™ for the treatment of uUTIs caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options.
  

• Repaid 6.500% Exchangeable Senior Subordinated Notes due 2025 (Exchangeable Notes): In January 2025, Iterum repaid the outstanding principal and interest due under its Exchangeable Notes, in accordance with their terms.

• Expansion of Patent Estate: The Australian Patent Office (IP Australia) has issued Iterum a Notice of Allowance for Australian patent application number 2019281018 entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof” that covers the use of a combination of sulopenem etzadroxil and probenecid in treating multiple diseases, including uncomplicated urinary tract infection. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of an Australian patent after administrative processes are completed. The Australian patent scheduled to issue from this application will expire June 7, 2039, absent any extensions.
  

Fourth Quarter and Full Year 2024 Financial Results

Cash and cash equivalents were $24.1 million as of December 31, 2024. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents, including $4.8 million of net proceeds raised under its at-the-market offering program from January 1, 2025 through February 6, 2025, will be sufficient to fund its operations into the second half of 2025.   The foregoing estimate gives effect to the repayment of the Exchangeable Notes in January 2025 and includes Iterum’s currently planned pre-commercialization activities. As of February 6, 2025, Iterum had approximately 34.6 million ordinary shares outstanding.

Cost of sales expenses for the fourth quarter and full year 2024 were $0.3 million and $0.3 million, respectively, and represents the amortization related to the finite-lived intangible asset recognized in relation to the regulatory milestone payment payable to Pfizer upon approval of ORLYNVAH™ by the FDA.

Research and development (R&D) expenses for the fourth quarter and full year 2024 were $1.3 million and $10.5 million, respectively, compared to $9.7 million and $40.0 million for the same periods in 2023. The decrease for the three- and twelve-month periods was primarily due to a decrease in clinical trial costs associated with the REASSURE trial.

General and administrative (G&A) expenses for the fourth quarter and full year 2024 were $2.1 million and $8.0 million, respectively, compared to $1.7 million and $7.5 million for the same periods in 2023. The increase for the three-month period was primarily due to an increase in legal fees. The increase for the full year was primarily due to an increase in legal fees and an increase in consultants used to support pre-commercial activities.

Adjustments to the fair value of derivatives for the fourth quarter and full year 2024 were $2.0 million and $3.3 million, respectively, compared to $0.3 million and ($11.1 million) for the same periods in 2023. The non-cash adjustment for the fourth quarter 2024 and full year 2024 primarily related to an increase in the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the Royalty-Linked Notes) upon the FDA’s approval of our NDA for ORLYNVAH™ and due to the passage of time. The non-cash adjustment for the full year 2023 primarily related to a decrease in the fair value of the Royalty-Linked Notes due to a reduction in management’s revenue forecast of U.S. sulopenem sales.

Net loss for the fourth quarter and full year 2024 was $6.6 million and $24.8 million, respectively, compared to a net loss of $12.4 million and $38.4 million for the same periods in 2023. Non-GAAP1 net loss for the fourth quarter and full year 2024 of $3.4 million and $17.9 million, respectively, compared to a non-GAAP¹ net loss of $10.7 million and $43.8 million for the same periods in 2023.

Conference Call Details

• Iterum will host a conference call today, Friday, February 7, 2025 at 8:30 a.m. Eastern Time. The dial-in information for the call is as follows: United States: 1 833 470 1428; International: 1 404 975 4839; Access code: 719739
  

Non-GAAP Financial Measures

To supplement Iterum’s financial results presented in accordance with U.S. generally accepted accounting principles (“GAAP”), Iterum presents non-GAAP net loss and non-GAAP net loss per share to exclude from reported GAAP net loss and GAAP net loss per share, intangible asset amortization ($0.3 million and $0.3 million); share-based compensation expense ($0.1 million and $0.4 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.2 million and $0.7 million); the non-cash amortization of the Exchangeable Notes ($0.6 million and $2.3 million); the interest expense associated with accrued interest on the promissory note issued to Pfizer Inc. ($0.3 million and $0.3 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($2.0 million and $3.3 million) for the three and twelve months ended December 31, 2024, respectively, and intangible asset amortization ($0.4 million and $1.7 million); share-based compensation expense ($0.1 million and $0.8 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.2 million and $0.8 million); the non-cash amortization of the Exchangeable Notes ($0.6 million and $2.4 million); and the non-cash adjustments to the fair value of derivatives and Royalty-Linked Notes ($0.3 million and ($11.1 million)) for the three and twelve months ended December 31, 2023, respectively.

Iterum believes that the presentation of non-GAAP net loss and non-GAAP net loss per share, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by investors, analysts, and Iterum’s management in assessing Iterum’s performance and results from period to period. These non-GAAP financial measures closely align with the way management measures and evaluates Iterum’s performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net loss or other financial measures calculated in accordance with GAAP. Non-GAAP net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and represents GAAP net loss, which is the most directly comparable GAAP measure, adjusted to exclude intangible asset amortization; share-based compensation expense; the interest expense associated with accrued interest on the Exchangeable Notes; the non-cash amortization of the Exchangeable Notes; the interest expense associated with accrued interest on the promissory note issued to Pfizer Inc.; and the non-cash adjustments to the fair value of derivatives and Royalty-Linked Notes for the three and twelve months ended December 31, 2024 and December 31, 2023. Because of the non-standardized definitions of non-GAAP financial measures, non-GAAP net loss and non-GAAP net loss per share used by Iterum in this press release and accompanying tables has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconciliation of non-GAAP net loss to GAAP net loss and non-GAAP net loss per share to GAAP net loss per share have been provided in the tables included in this press release.

About Iterum Therapeutics plc

Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.

About ORLYNVAH™

ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTI. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.

Cautionary Note Regarding Forward-looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum’s plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™, the expected issuance of an Australian patent following receipt of a notice of allowance in relation thereto and the term and coverage provided by such patent on issue, the sufficiency of Iterum’s cash resources to fund its operating expenses into the second half of 2025, Iterum’s strategic process to sell, license, or otherwise dispose of its rights to ORLYNVAH™, and Iterum’s ability to complete pre-commercialization activities for ORLYNVAH™, pending the outcome of Iterum’s strategic process.   In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum’s control, including risks and uncertainties concerning the outcome, impact, effects and results of Iterum’s evaluation of strategic alternatives, including the terms, timing, structure, value, benefits and costs of any strategic alternatives, Iterum’s ability to complete a strategic alternative transaction, Iterum’s ability to raise sufficient capital and successfully prepare and implement commercialization plans for ORLYNVAH™ with a commercial partner or directly, including the Iterum’s ability to build and maintain a sales force and prepare for commercial launch of ORLYNVAH™, if Iterum is unsuccessful at entering into or completing a strategic transaction, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at entering into or completing a strategic transaction or preparing and implementing commercialization plans for ORLYNVAH™, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, Iterum’s ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum’s expectations regarding how far into the future Iterum’s cash on hand will fund Iterum’s ongoing operations, Iterum’s ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K filed with the SEC on February 7, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum’s beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Investor Contact:
Judy Matthews
Chief Financial Officer 312-778-6073
IR@iterumtx.com

ITERUM THERAPEUTICS PLC
Consolidated Statement of Operations
(In thousands except share and per share data)
(Unaudited)
	Three months ended December 31,								Year ended December 31,
	2024				2023				2024				2023
Costs and expenses:
Cost of sales	$	(254	)		$	-			$	(254	)		$	-
Research and development		(1,299	)			(9,744	)			(10,458	)			(39,992	)
General and administrative		(2,117	)			(1,687	)			(7,984	)			(7,476	)
Total operating expenses		(3,670	)			(11,431	)			(18,696	)			(47,468	)
Operating loss		(3,670	)			(11,431	)			(18,696	)			(47,468	)
Interest expense, net		(874	)			(405	)			(2,522	)			(1,428	)
Adjustments to fair value of derivatives		(2,043	)			(305	)			(3,269	)			11,056
Other income, net		30				(79	)			(47	)			82
Income tax expense		(25	)			(142	)			(240	)			(613	)
Net loss attributable to ordinary shareholders	$	(6,582	)		$	(12,362	)		$	(24,774	)		$	(38,371	)
Net loss per share attributable to ordinary shareholders – basic and diluted	$	(0.25	)		$	(0.94	)		$	(1.26	)		$	(2.96	)
Weighted average ordinary shares outstanding – basic and diluted		26,687,281				13,180,447				19,699,260				12,962,362
Reconciliation of non-GAAP net loss to GAAP net loss
Net loss - GAAP	$	(6,582	)		$	(12,362	)		$	(24,774	)		$	(38,371	)
Intangible asset amortization		254				432				254				1,719
Share based compensation		89				139				363				784
Interest expense - accrued interest and amortization on exchangeable notes		756				782				3,011				3,150
Interest on promissory note - non-cash		300				-				300				-
Adjustments to fair value of derivatives		2,043				305				3,269				(11,056	)
Non-GAAP net loss	$	(3,140	)		$	(10,704	)		$	(17,577	)		$	(43,774	)
Net loss per share attributable to ordinary shareholders – basic and diluted	$	(0.25	)		$	(0.94	)		$	(1.26	)		$	(2.96	)
Non-GAAP net loss per share attributable to ordinary shareholders – basic and diluted	$	(0.12	)		$	(0.81	)		$	(0.89	)		$	(3.38	)
ITERUM THERAPEUTICS PLC
Consolidated Balance Sheet Data
(In thousands)
(Unaudited)
	As of				As of
	December 31,				December 31,
	2024				2023
Cash, cash equivalents and short-term investments	$	24,159			$	23,964
Intangible asset, net		19,746				-
Other assets		690				2,295
Total assets	$	44,595			$	26,259
Exchangeable notes	$	14,463			$	11,453
Royalty-linked notes		10,771				7,503
Long-term debt, less current portion		20,300				-
Other liabilities		3,142				13,706
Total liabilities	$	48,676			$	32,662
Total shareholders' deficit		(4,081	)			(6,403	)
Total liabilities and shareholders' deficit	$	44,595			$	26,259

_____________________________________
¹ Definition and reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release

FAQ

What was ITRM's cash position at the end of 2024?

Iterum Therapeutics had $24.1 million in cash and cash equivalents as of December 31, 2024.

When did ITRM receive FDA approval for ORLYNVAH?

ITRM received FDA approval for ORLYNVAH in the fourth quarter of 2024 for treating uncomplicated urinary tract infections.

How much did ITRM reduce its R&D expenses in 2024?

ITRM reduced its R&D expenses from $40.0 million in 2023 to $10.5 million in 2024, primarily due to decreased clinical trial costs.

What is the expected cash runway for ITRM as of February 2025?

ITRM expects its current cash position, including $4.8M raised through ATM offering in early 2025, to fund operations into the second half of 2025.

How much did ITRM's net loss improve in 2024 compared to 2023?

ITRM's net loss improved to $24.8 million in 2024 from $38.4 million in 2023.